cardiology
ACS

AF and diabetes: DOAC better than warfarin for preventing cardiac events


Rivaroxaban is associated with fewer major adverse cardiac events (MACE) and major adverse limb events (MALE) than warfarin in patients with non-valvular atrial fibrillation and comorbid type 2 diabetes, a study shows. A retrospective claims analysis in the US of more than 10,000 patients on rivaroxaban and almost 14,000 warfarin users found rivaroxaban was associated ...

Already a member?

Enter your email to keep reading.


OR